Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 313-319

  Chung, Mathew H ^a   Gupta, Rishab K ^a   Hsueh, Eddy ^a   Essner, Richard ^a   Ye, Wei ^a   Yee, Reynold ^a   Morton, Donald L ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CANVAXIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERFERON; TUMOR ANTIGEN; CANCER ANTIBODY; TA90 IMMUNE COMPLEX;

ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MELANOMA; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; UNIVARIATE ANALYSIS; ACTIVE IMMUNIZATION; ADULT; AGED; ANTIBODY PRODUCTION; BLOOD; DISEASE FREE SURVIVAL; FEMALE; IMMUNOLOGY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY, ACTIVE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037440128     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.068     Document Type: Article

References (53)

1. Flaherty LE: Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma. Cancer J Sci Am 6:S15-S20, 2000
2. McDermott DF, Mier JW, Lawrence DP, et al: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2b in patients with metastatic melanoma. Clin Cancer Res 6:2201-2208, 2000
3. Balch CM, Murad TM, Soong SJ, et al: A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 188:732-742, 1978
4. Balch CM: The role of elective lymph node dissection in melanoma: Rationale, results, and controversies. J Clin Oncol 6:163-172, 1988
5. Coit D, Sauven P, Brennan M: Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg 125:322-326, 1990
6. Kim SH, Garcia C, Rodriguez J, et al: Prognosis of thick cutaneous melanoma. J Am Coll Surg 188:241-247, 1999
7. Gershenwald JE, Mansfield PF, Lee JE, et al: Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma. Ann Surg Oncol 7:160-165, 2000
8. Morton DL, Foshag LJ, Hoon DS, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
9. Morton DL, Hoon DS, Nizze JA, et al: Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci 690:120-134, 1993
10. Jones RC, Kelley M, Gupta RK, et al: Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model. Ann Surg Oncol 3:437-445, 1996
11. Hsueh EC, Nathanson L, Foshag LJ, et al: Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 85:2160-2169, 1999
12. Hsueh EC, Gupta RK, Qi K, et al: Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16:2913-2920, 1998
13. Chan AD, Morton DL: Active immunotherapy with allogeneic tumor cell vaccines: Present status. Semin Oncol 25:611-622, 1998
14. Euhus DM, Gupta RK, Morton DL: Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 29:247-254, 1989
15. Chi DD, Merchant RE, Rand R, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143-2152, 1997
16. Gupta RK, Morton DL: Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody: III. Physicochemical properties. J Natl Cancer Inst 72:83-92, 1984
17. Gupta RK, Morton DL: Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody: II. Immunobiologic characterization. J Natl Cancer Inst 72:75-82, 1984
18. Gupta RK, Morton DL: Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody: I. Purification and development of a radioimmunoassay. J Natl Cancer Inst 72:67-74, 1984
19. Hoon DS, Yuzuki D, Hayashida M, et al: Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 154:730-737, 1995
20. Huang SK, Okamoto T, Morton DL, et al: Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Invest Dermatol 111:662-667, 1998
21. Nishinaka Y, Ravindranath MH, Irie RF: Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment. Cancer Res 56:5666-5671, 1996
22. Ravindranath MH, Morton DL, Irie RF: An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49:3891-3897, 1989
23. Ravindranath MH, Tsuchida T, Morton DL, et al: Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 67:3029-3035, 1991
24. Ravindranath MH, Amiri AA, Bauer PM, et al: Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma. Cancer 79:1686-1697, 1997
25. Sarantou T, Chi DD, Garrison DA, et al: Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57:1371-1376, 1997
26. Tai T, Cahan LD, Tsuchida T, et al: Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607-612, 1985
27. Tai T, Paulson JC, Cahan LD, et al: Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci U S A 80:5392-5396, 1983
28. Tsuchida T, Saxton RE, Morton DL, et al: Gangliosides of human melanoma. J Natl Cancer Inst 78:45-54, 1987
29. Okamoto T, Irie RF, Fujii S, et al: Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 111:1034-1039, 1998
30. Morioka N, Kikumoto Y, Hoon DS, et al: A decapeptide (Gln-Asp-Leu-Thr- Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by cytotoxic T lymphocytes in melanoma patients. J Immunol 153:5650-5658, 1994
31. Takahashi T, Conforti A, Kikumoto Y, et al: Augmentation of IgM antibody to gp43 tumor-associated antigen-peptide by polyvalent melanoma cell vaccine. J Clin Immunol 18:299-305, 1998
32. Tsuchida T, Saxton RE, Morton DL, et al: Gangliosides of human melanoma. Cancer 63:1166-1174, 1989
33. Gupta RK, Morton DL: Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J Natl Cancer Inst 70:993-1004, 1983
34. Wong JH, Gupta RK, Morton DL: Recovery of a cell surface fetal antigen and antibody in stage I melanoma patients. Cancer Immunol Immunother 27:142-146, 1988
35. Wong JH, Xu SH, Gupta RK, et al: Tumor associated antigen immune complexes. Arch Surg 125:187-191, 1990
36. Doi F, Chi DDJ, Charuworn BB, et al: Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int J Cancer 65:454-459, 1996
37. Cheresh DA, Reisfeld RA, Varki AP: O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science 225:844-846, 1984
38. Wilson BS, Imai K, Natali PG, et al: Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer 28:293-300, 1981
39. Tafra L, Dale PS, Wanek LA, et al: Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 110:119-129, 1995
40. Morton DL, Hsueh EC, Essner R, et al: Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236:438-449, 2002
41. Hsueh EC, Essner R, Foshag LJ, et al: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549-4554, 2002
42. Morton DL, Barth A: Vaccine therapy for malignant melanoma. CA Cancer J Clin 46:225-244, 1996
43. Hsueh EC, Gupta RK, Yee R, et al: Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol 7:232-238, 2000
44. Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg 127:392-399, 1992
45. Morton DL, Thompson JF, Essner R, et al: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Multicenter trial. Ann Surg 230:453-465, 1999
46. Euhus DM, Gupta RK, Morton DL: Detection of a tumor-associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1-40F4) in enzyme immunoassay. J Clin Lab Anal 3:184-190, 1989
47. O'Day SJ, Gammon G, Boasberg PD, et al: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17:2752-2761, 1999
48. DiFronzo LA, Gupta RK, Essner R, et al: Enchanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer Stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 20:3242-3248, 2002
49. Takahashi T, Johnson TD, Nishinaka Y, et al: IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 112:205-209, 1999
50. Kim SK, Ragupathi G, Cappello S, et al: Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 19:530-537, 2001
51. Basalp A, Cirakoglu B, Bermek E: Enhancement of the immune response to hepatitis B virus vaccine by antigen specific IgM. Immunol Lett 73:1-6, 2000
52. Ollert MW, David K, Schmitt C, et al: Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci U S A 93:4498-4503, 1996
53. MacLean GD, Reddish MA, Koganty RR, et al: Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 19:59-68, 1996